342 related articles for article (PubMed ID: 24400544)
1. [Serious organ damage and intractable clinical conditions in rheumatic and connective tissue disease--progress in pathophysiology and treatment. Topics: II. Clinical conditions special attention needed to be paid to; 3. Opportunistic infections].
Sumida K; Ubara Y
Nihon Naika Gakkai Zasshi; 2013 Oct; 102(10):2631-8. PubMed ID: 24400544
[No Abstract] [Full Text] [Related]
2. [Opportunistic infections in patients with collagen disease].
Tanaka Y; Saito K
Nihon Naika Gakkai Zasshi; 2004 Aug; 93(8):1654-9. PubMed ID: 15384698
[No Abstract] [Full Text] [Related]
3. Opportunistic Infections in Biological Therapy, Risk and Prevention.
Bryant PA; Baddley JW
Rheum Dis Clin North Am; 2017 Feb; 43(1):27-41. PubMed ID: 27890172
[TBL] [Abstract][Full Text] [Related]
4. [Infections during antirheumatic treatment].
Kneitz C
Dtsch Med Wochenschr; 2014 Aug; 139(31-32):1593-5. PubMed ID: 25076314
[No Abstract] [Full Text] [Related]
5. [Pulmonary infections in patients with rheumatoid arthritis].
Takayanagi N; Tsuchiya Y; Tokunaga D; Miyahara Y; Yamaguchi S; Saito H; Ubukata M; Kurashima K; Yanagisawa T; Sugita Y
Nihon Kokyuki Gakkai Zasshi; 2007 Jun; 45(6):465-73. PubMed ID: 17644942
[TBL] [Abstract][Full Text] [Related]
6. Infection and anti-tumor necrosis factor-alpha therapy.
Zandman-Goddard G
Isr Med Assoc J; 2003 Nov; 5(11):814-6. PubMed ID: 14650109
[No Abstract] [Full Text] [Related]
7. Serious infections associated with anticytokine therapies in the rheumatic diseases.
Giles JT; Bathon JM
J Intensive Care Med; 2004; 19(6):320-34. PubMed ID: 15523118
[TBL] [Abstract][Full Text] [Related]
8. Clinical evaluation of patients with inflammatory connective tissue diseases complicated by cytomegalovirus antigenemia.
Yoda Y; Hanaoka R; Ide H; Isozaki T; Matsunawa M; Yajima N; Shiozawa F; Miwa Y; Negishi M; Kasama T
Mod Rheumatol; 2006; 16(3):137-42. PubMed ID: 16767551
[TBL] [Abstract][Full Text] [Related]
9. Pneumocystis jirovecii pneumonia in systemic autoimmune rheumatic disease: A case-control study.
Tadros S; Teichtahl AJ; Ciciriello S; Wicks IP
Semin Arthritis Rheum; 2017 Jun; 46(6):804-809. PubMed ID: 27814896
[TBL] [Abstract][Full Text] [Related]
10. Pneumocystis jiroveci pneumonia in rheumatic disease: a 20-year single-centre experience.
Mecoli CA; Saylor D; Gelber AC; Christopher-Stine L
Clin Exp Rheumatol; 2017; 35(4):671-673. PubMed ID: 28134084
[TBL] [Abstract][Full Text] [Related]
11. [Collagen diseases with opportunistic infections].
Takabayashi K; Hanaoka H
Nihon Rinsho Meneki Gakkai Kaishi; 2004 Jun; 27(3):156-63. PubMed ID: 15291252
[TBL] [Abstract][Full Text] [Related]
12. Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists.
García-Doval I; Pérez-Zafrilla B; Descalzo MA; Roselló R; Hernández MV; Gómez-Reino JJ; Carmona L;
Ann Rheum Dis; 2010 Oct; 69(10):1751-5. PubMed ID: 20551153
[TBL] [Abstract][Full Text] [Related]
13. Factors associated with withdrawal of the anti-TNFα biologics in the treatment of rheumatic diseases: data from the Hong Kong Biologics Registry.
Mok CC; Chan KY; Lee KL; Tam LS; Lee KW;
Int J Rheum Dis; 2014 Dec; 17 Suppl 3():1-8. PubMed ID: 24382315
[TBL] [Abstract][Full Text] [Related]
14. Biologics and risk of tuberculosis in autoimmune rheumatic diseases: A real-world clinical experience from India.
Shobha V; Chandrashekara S; Rao V; Desai A; Jois R; Dharmanand BG; Kumar S; Kumar P; Dharmapalaiah C; Mahendranath KM; Prasad S; Daware MA; Singh Y; Karjigi U; Nagaraj S; Anupama KR
Int J Rheum Dis; 2019 Feb; 22(2):280-287. PubMed ID: 30168281
[TBL] [Abstract][Full Text] [Related]
15. Use of the T-SPOT.TB assay to detect latent tuberculosis infection among rheumatic disease patients on immunosuppressive therapy.
Behar SM; Shin DS; Maier A; Coblyn J; Helfgott S; Weinblatt ME
J Rheumatol; 2009 Mar; 36(3):546-51. PubMed ID: 19228655
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and safety of lower dose sulfamethoxazole/trimethoprim therapy for Pneumocystis jirovecii pneumonia in patients with systemic rheumatic diseases: A retrospective multicenter study.
Ohmura SI; Naniwa T; Tamechika SY; Miyamoto T; Shichi D; Kazawa N; Iwagaitsu S; Maeda S; Wada JI; Niimi A
J Infect Chemother; 2019 Apr; 25(4):253-261. PubMed ID: 30642768
[TBL] [Abstract][Full Text] [Related]
17. Soft tissue manifestations of mycobacterial infection in patients with rheumatic diseases.
Lateef A; Vasoo S; Boey ML
Ann Acad Med Singap; 2007 Feb; 36(2):152-3. PubMed ID: 17364085
[No Abstract] [Full Text] [Related]
18. COVID-19-associated opportunistic infections: a snapshot on the current reports.
Abdoli A; Falahi S; Kenarkoohi A
Clin Exp Med; 2022 Aug; 22(3):327-346. PubMed ID: 34424451
[TBL] [Abstract][Full Text] [Related]
19. [Serious organ damage and intractable clinical conditions in rheumatic and connective tissue disease--progress in pathophysiology and treatment. Topics: I. Damage to important organs whose early treatment makes a big difference; 5. Hepatic and gastrointestinal manifestations in collagen vascular diseases].
Shimoda S; Akahoshi M; Tsukamoto H
Nihon Naika Gakkai Zasshi; 2013 Oct; 102(10):2567-74. PubMed ID: 24400536
[No Abstract] [Full Text] [Related]
20. Latent tuberculosis infection detection and active tuberculosis prevention in patients receiving anti-TNF therapy: an Italian nationwide survey.
Cantini F; Lubrano E; Marchesoni A; Mathieu A; Olivieri I; Salvarani C; Scarpa R; Spadaro A
Int J Rheum Dis; 2016 Aug; 19(8):799-805. PubMed ID: 26172207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
